A Pfizer-associated Boston startup that uses AI and machine learning to aid drug companies with development and discovery of new drugs was given $68 million from the NIH. PostEra will join with Memorial Sloan Kettering Cancer Center and the Drugs for Neglected Diseases Initiative to use the grant to discover new antivirals and push them into clinical studies.

PostEra has already developed experience in this field through it partnership with Pfizer earlier this year, where it helped search for antivirals to combat COVID-19, and looked for cancer treatments.